Study record · Semaglutide (oral)
OASIS 1 oral semaglutide 50 mg obesity trial
Estimated mean weight change was -15.1% versus -2.4% placebo; 85% versus 26% achieved at least 5% loss.
Key result
Estimated mean weight change was -15.1% versus -2.4% placebo; 85% versus 26% achieved at least 5% loss.
Study details
Study designRandomized double-blind placebo-controlled trial
PhasePhase III
PopulationAdults with overweight/obesity without diabetes
Sample size667
RouteOral
Regimen / exposureEscalated to 50 mg once daily
Duration68 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change and >=5% loss
Safety resultGI adverse events occurred in 80% versus 46% with placebo; overall AEs 92% versus 86%.
Key limitationsThe 50 mg obesity regimen is study-specific and distinct from lower-dose oral semaglutide products/indications.
Registry / identifierPMID 37385278 / NCT05035095